This work concerns the problem of optimizing the drug doses in the treatment of AIDS by looking for a balance between the therapeutic response and the side effects. Extensive computer simulation and comparison with the constant dose scheme evaluate the results. For some few cases the results are also compared with actual clinical data. A mathematical model describing the dynamics of HIV virus and CD4 cells is initially fitted to actual published clinical data. The identified model is then used to compute the sub-optimal drug doses for the treatment of AIDS by a direct method of optimization using a performance index of Bolza type. The sub-optimal treatment scheme is shown to achieve a therapeutic response close to the constant dose strategy, but with lower cost, as measured by the proposed performance index.
-Introduction
Mathematical models of dynamical systems in the form of differential equations are used extensively, for example, in computer simulations for investigation of the dynamics of viral and lymphocyte populations. The model used in this work is an adapted version of the one proposed by Tan, Wu in [16] . A performance index, which takes into account the number of non-infected CD4 cells, and the administered doses of the drugs evaluate the effectiveness of a particular treatment scheme. The optimal control problem resulting by combining the mathematical model and the performance index is solved numerically by direct optimization techniques. The problem of optimal control of the chemotherapy of HIV has also been considered by Kirschner, Lenhart & Serbin in [5] .
-Mathematical Models
A number of mathematical models have been proposed in the field of immunology, which can be found, for instance, in [1, 6, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18 and 19], , among other works. The model in [10] considers a system of ordinary differential equations with four variables: x i , y, v i and z i which denote respectively strain-specific CD4 cells, total CD4 cells, virus population and cross-reactive CD4 cells. The authors simulate the mathematical model with immunotherapy starting at different times after infection. The work in [11] compares three dynamic models of HIV infection. The first is the simpler and contains three variables x, y and v denoting, respectively, uninfected cells, infected cells and free virus. Another model uses four variables where the first three variables are again x, y, v as before and the fourth variable z represents CTL lymphocytes. The last model has four variables and includes the variability of virus. The model in [14] involves four differential equations in variables R, L, E and V which represent, respectively, uninfected CD4, latent infected cells, infected cells and free viruses. This model can be used to simulate the initial phase of infection. [13] presented a new model that considers the interaction between CTL and the multiple epitopes of a genetically variable pathogen. The version proposed in [12] includes the population of mutant virus, and provides analytic approximation for the rate of emergence of resistant viruses. This model comprises five equations and the results match the experimental data of three infected patients treated with Neverapine (NVP). In [9] the proposed model uses eight differential equations with variables such as: naïve cells; cells that do not recognize HIV but are only activated by other antigen; cells that recognize HIV and are stimulated by its presence to divide and produce activated cells; memory cells specific to HIV; free viruses and viruses that have lost their ability to attach to CD4 T cells.
Wick in [19] proposed a model of T cell dynamics in which rising activation rates produced falling T-cell counts and showed that apoptosis and proliferation must nearly balance. His model has four differential equations composed by: naïve T cells and memory cells in activated and resting states. The model in [20] focuses on the simulation of protease inhibitors and development of drug-resistant HIV strains. The model is composed of eleven differential equations and there is a coupling between organisms that are infected with resistant and non-resistant HIV strains. The analysis shows that multidrug therapy can lead to significantly high prevalence of multi-drug-resistant HIV strains. In [16, 17] it is proposed a discrete stochastic model for the HIV pathogenesis under treatment by antiviral drugs. The model has four differential equations and stochastic terms in the variables that represent the number of latent infected T cells. It has also stochastic components on infectious free HIV and non-infectious free HIV variables.
The mathematical model presented by Tan, Wu in [16] with deterministic terms was adopted here. The dynamics is described by the differential equations In the presence of free HIV (x 4 ), uninfected cells x 1 can be infected to become x 2 cells and x 3 cells, depending of probability of cells become active or latent infected with rate ω. The x 2 cells can be activated to become x 3 cells. The activation rate is k 2. The x 3 cells are short lived and will normally be killed upon activation with death rate μ 3 . The x 1, x 2 cells and x 4 free virus have finite life and the death rate in this model is μ 1 , μ 2 and μ v respectively. When x 3 cells die free viruses x 4 are released with rate N(t) described by (4) . Drugs such as reverse transcriptase inhibitors (zidovudine and lamivudine) and protease inhibitors (saquinavir, indinavir and ritonavir) affect the parameters k 1 and k 2 .
-The Sub-Optimal Control
The objective in a general optimal control problem is to find a control-input m(t) that minimizes the cost function
where t 0 and t f are the initial and final times; h and g are given positive scalar functions. Moreover, x(.) and m(.) are constrained by the state equation
In the specific problem treated in this work,
where k 10 , k 20 , α 1 , α 2 , φ 1 , φ 2 , γ 1 , γ 2 , ε 1 and ε 2 are constants.
Optimal control problems can be solved by indirect or direct methods. In the solution using an indirect method, one is required to solve a boundary value problem with 2n equations corresponding to n state and n adjoint variables if Maximum Principle is invoked or to solve a partial differential equation if Dynamic Programming [2, 4, 7] is used. In the solution using a direct method, one attempts to minimize directly the performance measure (7) after a suitable parameterisation of the admissible control inputs m(t). Here, a direct method proposed by Jacob in [3] is used. The parameterisation of the input function m(t) involves, in the present case, a subset of the coefficients of expansion in sine functions and only approximations to the actual optimal m(t) are obtained. However, those sub-optimal control inputs are found to provide improved treatment results when compared to fixed drug doses.
Three cases are considered in this work: monotherapy (either reverse transcriptase inhibitor or protease inhibitor) and combination of both.
First Case
Sub-optimal administration of reverse transcriptase inhibitor In this case k 2 is assumed to be constant (m 2 (t) = 0 ∀t) while k 1 depends on the drug dose: 
-Parameterisation of the Input Control
This work uses a direct method to minimize the cost function (5) based on the numerical algorithm proposed by Jacob in [3] 
-Simulation Results
The actual clinical data were extracted from Tan [16] and refers to a patient that contracted HIV at the age of 11 years and his T cell counts were measured on 16 occasions. Tables 1 and 2 and the parameters  used in the simulations in Tables 3, 4 , 5 and 6. Firstly the model parameters were adjusted by an identification procedure to match the available data. Simulation results in the figures 1-5 correspond to the present case study. In the figures the actual data set is shown to fit the simulated model using the identified parameters and without treatment. The control variables were constrained to be in the range (300 mg) ≤ m 1 (t) ≤ (900 mg) {reverse transcriptase inhibitor} and (300 mg) ≤ m 2 (t) ≤ (900 mg) {protease inhibitor}, respectively. For others patients the constraints were relaxed to (0 mg) ≤ m 1 (t) ≤ (1500 mg) and (0 mg) ≤ m 2 (t) ≤ (1500 mg). In all cases the expression of the control variable was where the constants α 1 = α 2 = 0.005 can be interpreted as the activity of the drugs. These controls m 1 (t), m 2 (t) were found by applying an optimization method for minimizing the performance index (5).
It is worth noting that the optimal drug doses varies from patient to patient, because of the differences on the actual models parameters. Figure 6 shows typical trajectories (projections on x 4 , x 1 plane) under sub-optimal and constant dose treatment schemes. 
-Conclusion
The new performance index help the numerical method to solve the problem and to found a solution fitted of actual data. Of all patients, only one case shows the same final result with actual data. All others treatment (theoretical) were better than the conventional treatment with the constant administration of drugs. The polynomial approach was good using degree 5 and seven terms in the representation of controls variables and the optimal solutions run about 10 times in all cases studied. We use three types of control in the administration of drugs: only reverse transcriptase inhibitor, only protease inhibitor and cocktail of drugs with two types of inhibitors.
The results indicate that the best situation is with the use of cocktails, but when we use the optimal control in the performance index, the results with cocktail in optimal administration was better than the one without it. This is important because there is some relation between the performance index and side effects of drugs in the patients. This article showed a method to design of treatment schemes using optimal control theory for patients with AIDS. 
